HER۲ Amplification in Non-Mutant RAS Status in Patients with Metastatic Colorectal Cancer and the ۲-Year Survival Rate

Introduction: HER۲ amplification is a therapeutic target in breast and stomach cancer, but the relationship between HER۲ and response to treatment in metastatic colorectal cancer has not been fully determined. This study investigated the incidence of HER۲ overexpression in non-mutant RAS patients with metastatic colorectal cancer to determine the two-year survival rate in patients referred to Imam Khomeini Hospital in Sari between ۲۰۱۴-۲۰۱۸. Material and Methods: This cohort study was conducted between ۲۰۱۴ and ۲۰۱۸ among patients with metastatic colorectal cancer who were identified as non-mutant (wild) NRAS, KRAS, and BRAF genes. Patients received cetuximab. The clinical course of the patients was evaluated simultaneously during this evaluation period, and the two-year survival rate of the patients and the response to cetuximab were evaluated. Data were entered into SPSS software version ۲۴ and analyzed. Results: Twenty-five patients were examined, ۶۰% were men. The most common symptom in patients was abdominal pain (۳۲%). The majority (۷۲%) of the study patients did not undergo surgery, ۲۴% underwent hemicolectomy and ۴% underwent total colectomy. The incidence of HER۲ positive in women was higher than in men (۱۰% vs. ۶%) and in grade ۱ patients was higher than grade ۲ (۸.۳% vs. ۱.۱%). Forty-four percents of patients had positive two-year survival. Among patients with positive two-year survival, ۹.۱% were HER۲ positive and ۹۰.۹% were HER۲ negative. Conclusion: The results of the study showed that infectious causes (influenza) and underlying CLD including asthma were major causes of ARF in pregnant women. Thus, more careful attention is needed to control the underlying disease, and planning for easier access to the influenza vaccine can play an effective role in reducing the incidence of pulmonary infections.

کلیدواژه ها:

Cetuximab ، Colorectal Cancer ، HER۲